# Microbiome-mediated colonization resistance to and countermeasures of Klebsiella pneumoniae

**Authors:** Yongqiang Yang, Willem van Schaik, Alan McNally, Zhiyong Zong

PMC · DOI: 10.1038/s41467-026-69690-9 · Nature Communications · 2026-02-16

## TL;DR

This paper explores how the gut microbiome influences Klebsiella pneumoniae colonization and disease, and how the bacteria adapt to resist microbial defenses.

## Contribution

The paper highlights novel mechanisms by which K. pneumoniae adapts to gut commensals and suggests microbiome-based therapeutic strategies.

## Key findings

- Gut commensals provide colonization resistance against Klebsiella pneumoniae.
- K. pneumoniae adapts via multiple mechanisms to overcome this resistance.
- Microbiome-based therapies show potential for managing K. pneumoniae-related diseases.

## Abstract

Klebsiella pneumoniae intestinal colonization contributes to infectious and non-infectious diseases. Recent studies have uncovered the complex interplay between the gut microbiota and K. pneumoniae colonization, highlighting its role in disease development and progression and illustrating the potential of microbiome-based therapies.

Yang et al. summarize that Klebsiella pneumoniae affects infectious and non-infectious disease via gut colonization; commensals provide colonization resistance, but K. pneumoniae adapts via multiple mechanisms.

## Linked entities

- **Species:** Klebsiella pneumoniae (taxon 573)

## Full-text entities

- **Diseases:** ocular infections (MESH:D015817), urinary tract infections (MESH:D014552), Infection (MESH:D007239), inflammatory bowel diseases (MESH:D015212), bloodstream infections (MESH:D018805), invasive disease (MESH:D009361), infectious (MESH:D003141), hepatocellular carcinoma (MESH:D006528), nervous system infections (MESH:D009421), wound (MESH:D014947), respiratory tract infections (MESH:D012141), liver abscesses (MESH:D008100), liver diseases (MESH:D008107), meningitis (MESH:D008580), gut dysbiosis (MESH:D064806), intra-abdominal infections (MESH:D059413), non-alcoholic fatty liver disease (MESH:D065626), CRKP (MESH:D011014), non-infectious diseases (MESH:D000073296), auto-brewery syndrome (MESH:D018467), hypoxia (MESH:D000860), pyelonephritis (MESH:D011704), cystitis (MESH:D003556)
- **Chemicals:** BioRender (-), arginine (MESH:D001120), serine (MESH:D012694), butyrate (MESH:D002087), tilimycin (MESH:C000706649), LPS (MESH:D008070), threonine (MESH:D013912), glucose (MESH:D005947), carbon (MESH:D002244), lactulose (MESH:D007792), carbapenem (MESH:D015780), iron (MESH:D007501), gluconate (MESH:C030691)
- **Species:** Klebsiella oxytoca (species) [taxon 571], Phocaeicola dorei (species) [taxon 357276], Blautia coccoides [taxon 1532], Faecalibacterium prausnitzii (species) [taxon 853], Homo sapiens (human, species) [taxon 9606], Bifidobacterium bifidum (species) [taxon 1681], Escherichia coli (E. coli, species) [taxon 562], Lactobacillus (genus) [taxon 1578], Klebsiella pneumoniae (species) [taxon 573], Mus musculus (house mouse, species) [taxon 10090], Bifidobacterium pseudocatenulatum (species) [taxon 28026]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913986/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12913986/full.md

---
Source: https://tomesphere.com/paper/PMC12913986